28412 Federal Register / Vol. 60, No. 104 / Wednesday, May 31, 1995 / Notices

noted, such activities will be conducted

throughout the United States.

The application is available for

immediate inspection at the Federal

Reserve Bank indicated. Once the

application has been accepted for

processing, it will also be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing on the

question whether consummation of the

proposal can ‘‘reasonably be expected to

produce benefits to the public, such as

greater convenience, increased

competition, or gains in efficiency, that

outweigh possible adverse effects, such

as undue concentration of resources,

decreased or unfair competition,

conflicts of interests, or unsound

banking practices.’’ Any request for a

hearing on this question must be

accompanied by a statement of the

reasons a written presentation would

not suffice in lieu of a hearing,

identifying specifically any questions of

fact that are in dispute, summarizing the

evidence that would be presented at a

hearing, and indicating how the party

commenting would be aggrieved by

approval of the proposal.

Comments regarding the application

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than June 13, 1995.

A. Federal Reserve Bank of Dallas

(Genie D. Short, Vice President) 2200

North Pearl Street, Dallas, Texas 75201-

2272:

1. The Berens Corporation, Houston,

Texas; To engage de novo through its

subsidiary, Berens Credit Corporation,

Houston, Texas, in making and

arranging loans and other extensions of

credit, pursuant to § 225.25(b)(1); and

leasing activities, pursuant to §

225.25(b)(5) of the Board’s Regulation Y.

Board of Governors of the Federal Reserve

System, May 24, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–13211 Filed 5–30–95; 8:45 am]

BILLING CODE 6210–01–F

Societe Generale; Notice To Engage in

Nonbanking Activities

Societe Generale, Paris, France

(Notificant), has provided notice

pursuant to section 4(c)(8) of the Bank

Holding Company Act (12 U.S.C.

1843(c)(8)) (BHC Act) and § 225.23(a)(3)

of the Board’s Regulation Y (12 CFR

225.23(a)(3)), to acquire through its

subsidiary, FIMAT Futures USA, Inc.,

Chicago, Illinois (Company),

substantially all of the assets of Brody,

White & Company, Inc., New York, New

York (Brody White). Company currently

engages in a variety of futures

commission merchant and foreign

exchange-related activities. See Societe

Generale, 80 Federal Reserve Bulletin

649 (1994) (Societe Generale I) and

Societe Generale, 80 Federal Reserve

Bulletin 646 (1994) (Societe Generale II).

Upon acquisition of Brody White,

Company would expand its activities to

include becoming a clearing member of

the New York Cotton Exchange,

Commodity Exchange, Inc., Financial

Exchange, New York Futures Exchange

and the Coffee, Sugar & Cocoa

Exchange; purchasing and selling

through omnibus accounts futures and

options on futures on the London

Commodity Exchange and Winnipeg

Commodity Exchange; and acting as

riskless principal in connection with

spot, forward and over-the-counter

option transactions in the foreign

exchange market.

Notificant has stated that upon

acquisition of Brody White, Company

would continue to provide futures

commission merchant execution,

clearance and advisory services subject

to the same limitations, conditions and

commitments relied on by the Board in

Societe Generale I, with one exception.

In particular, Notificant proposes that

Company provide execution, clearance

and advisory services to commercial

hedger customers with net worths of

less than $1 million. The Board

previously has relied on commitments

that clearing-only services and futures

commission merchant services provided

with respect to futures and options on

futures on nonfinancial commodities

would be provided solely to

institutional customers, as defined in §

225.2(g) of Regulation Y. Notificant has

represented that these customers would

not be unsophisticated retail investors.

Notificant also has stated that in order

to address suitability and credit risk

issues, as well as any other possible

adverse effects, noninstitutional

customers would have to represent in

writing that they are engaged in bona

fide hedging transactions for purposes

of CFTC regulation 1.3(z) (17 CFR

1.3(z)), and Company would have a

system in place to detect any

unauthorized trading by these

customers in commodities other than

those as to which hedge margin status

has been granted. In addition, there

would be an initial credit review

process to determine whether a

customer’s proposed hedging activities

are appropriate in light of the

customer’s net worth and business

activities, as well as periodic reviews on

actual trading activities in the account.

Based on these facts, Notificant

maintains that providing the proposed

futures commission merchant services

to certain noninstitutional customers is

so closely related to banking as to be a

proper incident thereto.

Notificant also has stated that upon

acquisition of Brody White, Company

would purchase and sell, on the order

of investors as riskless principal, foreign

exchange in the spot, forward and overthe-counter option markets. Notificant

maintains that the Board previously has

determined that purchasing and selling

foreign exchange as riskless principal is

closely related to banking. See Banca

Commerciale Italiana, 76 Federal

Reserve Bulletin 649 (1990) (BCI).

Notificant has stated that Company

would provide the proposed riskless

principal services in accordance with

the limitations, commitments and

conditions relied on by the Board in

BCI. Notificant also has stated that

Company would continue to comply

with commitments made to the Board in

Societe Generale II that relate to

providing foreign exchange execution

and advisory services on a combined

basis.

In order to approve the proposal, the

Board must determine that the proposed

activities to be conducted by Company

‘‘can reasonably be expected to produce

benefits to the public, such as greater

convenience, increased competition, or

gains in efficiency, that outweigh

possible adverse effects, such as undue

concentration of resources, decreased or

unfair competition, conflicts of

interests, or unsound banking

practices.’’ 12 U.S.C. 1843(c)(8).

Notificant maintains that the proposal

would not produce any adverse effects.

Notificant also maintains that the

proposal would lead to increased

competition in the relevant markets,

better customer service, lower costs and

greater efficiency.

Any comments or requests for hearing

should be submitted in writing and

received by William W. Wiles,

Secretary, Board of Governors of the

Federal Reserve System, Washington,

D.C. 20551, not later than June 30, 1995.

Any request for a hearing on this notice

must, as required by § 262.3(e) of the

Board’s Rules of Procedure (12 CFR

262.3(e)), be accompanied by a

statement of the reasons why a written

presentation would not suffice in lieu of

a hearing, identifying specifically any

questions of fact that are in dispute,

summarizing the evidence that would

be presented at a hearing, and indicating

how the party commenting would be

aggrieved by approval of the proposal.

This notice may be inspected at the

offices of the Board of Governors or the

Federal Reserve Bank of New York.
Federal Register / Vol. 60, No. 104 / Wednesday, May 31, 1995 / Notices 28413

Board of Governors of the Federal Reserve

System, May 24, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–13212 Filed 5–30–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Advisory Committee on Immunization

Practices; Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meeting:

Name: Advisory Committee on

Immunization Practices (ACIP).

Times and Dates: 8:30 a.m.–6 p.m., June

28, 1995; 8:15 a.m.–3:30 p.m., June 29, 1995.

Place: CDC, Auditorium A, Building 2,

1600 Clifton Road, NE, Atlanta, Georgia

30333.

Status: Open to the public, limited only by

the space available.

Purpose: The committee is charged with

advising the Director, CDC, on the

appropriate uses of immunizing agents.

Matters to be discussed: The committee

will discuss the polio vaccine policy; the

approach to developing ACIP vaccine

recommendations; hepatitis A vaccine—use

in high endemic populations; varicella

update; ‘‘Vaccines for Children Program’’:

Hepatitis A, hepatitis B, varicella; adolescent

immunization visit; measles elimination

update; vaccine safety update: preference of

DTaP for 4th and 5th doses; ACIP

participation in the National Vaccine

Advisory Committee and the Advisory

Commission on Childhood Vaccines

Subcommittee on Vaccine Safety; measles

vaccine inflammatory bowel disease; largelinked database (LLDB) results; acellular

pertussis vaccine trial results; programmatic

strategies to increase immunization coverage;

pneumococcal conjugate vaccine;

harmonization of immunization

recommendations; update on progress

towards disease elimination goals; ACIP

recommendations and package inserts;

diphtheria and the New Independent States

update: the U.S. contingency plan; electronic

updating of ACIP recommendations; an

Injury Compensation Program update; and a

National Vaccine Program update. Other

matters of relevance among the committee’s

objectives may be discussed.

Agenda items are subject to change as

priorities dictate.

Contact person for more information:

Gloria A. Kovach, Committee Management

Specialist, CDC (1–B72), 1600 Clifton Road,

NE, Mailstop A20, Atlanta, Georgia 30333,

telephone 404/639–3851.

Dated: May 24, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 95–13209 Filed 5–30–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95N–0097]

New Monographs and Revisions of

Certain Food Chemicals Codex

Monographs; Opportunity for Public

Comment

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing an

opportunity for public comment on

pending changes to certain Food

Chemicals Codex specifications

monographs from the third edition and

its four supplements. One new

monograph and additions, revisions,

and corrections to current monographs

for certain substances used as food

ingredients are being prepared by the

National Academy of Sciences/Institute

of Medicine (NAS/IOM) Committee on

Food Chemicals Codex (the committee).

This material will be published in the

fourth edition of the Food Chemicals

Codex, which is scheduled for release in

March 1996. When the committee

completes its review of the comments,

it will incorporate any changes that it

makes in response to comments in

monographs published in supplements

to the fourth edition.

DATES: Written comments by August 14,

1995.

ADDRESSES: Submit written comments

and supporting data and documentation

to the NAS/IOM Committee on Food

Chemicals Codex, National Academy of

Sciences, 2101 Constitution Ave., NW.,

Washington, DC 20418. Copies of the

new monographs and proposed

revisions to current monographs may be

obtained from NAS (address above) or

the Dockets Management Branch (HFA–

305), Food and Drug Administration,

rm. 1–23, 12420 Parklawn Dr.,

Rockville, MD 20857. Requests for

copies should specify the monographs

desired.

FOR FURTHER INFORMATION CONTACT:

Fatima N. Johnson, Committee on

Food Chemicals Codex, Food and

Nutrition Board, National Academy

of Sciences, 2101 Constitution Ave.,

NW., Washington, DC 20418, 202–

334–2580; or

Paul M. Kuznesof, Center for Food

Safety and Applied Nutrition (HFS–

247), Food and Drug

Administration, 200 C Street, SW.,

Washington, DC 20204, 202–418–

3009.

SUPPLEMENTARY INFORMATION: By

contract with NAS/IOM, FDA supports

the preparation of the Food Chemicals

Codex, which is a compendium of

specifications for substances used as

food ingredients. Before any

specifications are included in a Food

Chemicals Codex publication, public

announcement is made in the Federal

Register.

FDA previously announced that the

committee was considering new

monographs and monograph revisions

for inclusion in the fourth edition of the

Food Chemicals Codex, which NAS/

IOM is now preparing. In addition, FDA

has given notice and an opportunity for

public comment on the policies adopted

by the committee for the fourth edition

on lead and heavy metals specifications

(58 FR 38129, July 15, 1993), and on

arsenic specifications (59 FR 11789,

March 14, 1994).

The committee will continue to

provide the opportunity for public

comment on intended changes in

monographs by means of Federal

Register notices before their inclusion

in supplements to the fourth edition.

Interested parties should submit all

suggestions with supporting

documentation to the National Academy

of Sciences at the above address.

FDA now gives notice that the

committee is soliciting comments and

information on certain proposed new

monographs and revisions to certain

additional current monographs. These

new monographs and revisions will be

published in the fourth edition of the

Food Chemicals Codex. The proposed

new monographs and revisions to

current monographs may be seen at the

Dockets Management Branch (address

above) between 9 a.m. and 4 p.m.,

Monday through Friday. Because the

publication timeframe for the fourth

edition, comments on monographs that

are the subject of this notice cannot be

considered for incorporation in the

fourth edition, which is scheduled for

release in March 1996, but will be

considered for incorporation in

supplements to the fourth edition.

Copies of the new monographs and

proposed revisions to current

monographs may be obtained from NAS

or the Dockets Management Branch.

Requests for copies should be identified

with the docket number found in

brackets in the heading of this